Molecular diagnostics is a technique that identifies and analyzes nucleic acids or proteins at a molecular level. This technique assesses the genetic makeup of an individual to identify a predisposition to any particular disease or condition and diagnose it.

The 360 Quadrant maps the molecular diagnostics companies based on criteria such as revenue, geographic presence, growth strategies, investments, and sales strategies for the market presence of the Molecular Diagnostics’ quadrant. While the top criteria for product footprint evaluation included Product (Reagents & Kits, Instruments, Services & Software), Technology (Polymerase Chain Reaction, Isothermal Nucleic Acid Amplification Technology, DNA Sequencing & Next-generation Sequencing, DNA Microarrays, In Situ Hybridization, Other Technologies), Test Type (Lab Tests, PoC Tests), Application ((Infectious Disease Diagnostics (Hepatitis, HIV, CT/NG, HAI, HPV, Tuberculosis, Influenza, Other Infectious Diseases), Oncology Testing (Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Other Cancers), Genetic Testing, COVID-19, Other Applications), Product Launches, Product Approvals, and R&D Expenditure.

Key trends highlighted in 360 Quadrant’s study include: